29 August 2022
SHARE NOW
Allogeneic
Autologous
Cell Therapy
Gene Therapy
Ohad Karnieli, Founder and CEO of Adva Biotechnology, discusses the clinical potential for cell and gene therapies, as well as the gap that needs bridging in order to transform advanced therapies from scientific success to available cures.
In this short interview, Ohad discusses where we are in revolutionizing cancer treatment, as well as what gaps still need to be bridged in delivering advanced therapies to patients.
Hear more from Ohad at Advanced Therapies Europe – join his session at 13:30 on Wednesday 31st August, titled, ‘Exploring the Shift Towards Point-of-Care Automation & Decentralised Manufacturing.
This interview has been produced in partnership with Adva Biotechnology.
How are you enjoying this interview? Let us know your thoughts, here >>
While we have you…
We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.
More like this
Eureka Therapeutics Awarded $10.6M CIRM Grant for T-Cell Therapy in Pediatric Liver Cancer
Eureka Therapeutics has received a $10.6 million grant from the California Institute for Regenerative Medicine (CIRM) to support its ongoing ARYA-2 Phase I study of ET140203 for the treatment of refractory/relapsed liver cancer for pediatric patients.
8 June 2023
Cell and Gene Therapy Catapult Open New Edinburgh, UK, Facilities
UK-based independent innovation and technology organization Cell and Gene Therapy Catapult (CGT Catapult), has officially opened new laboratories and offices in Edinburgh, Scotland, UK, BioQuarter – enhancing Edinburgh’s role as a hub for cell therapies.
7 June 2023
BioCentriq® Unveils LEAP™ Advanced Therapy Platform, Enabling Rapid Patient Access for Early-Stage Biotech Companies
BioCentriq launched their new LEAP™ Advanced Therapy Platform at the 29th International Society for Cell & Gene Therapy (ISCT) annual event with proven assets and expertise to help early-stage biotech companies effectively deliver to patients without compromising quality.
5 June 2023
Discover more like this
